511 related articles for article (PubMed ID: 34126195)
1. Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids.
Koh V; Chakrabarti J; Torvund M; Steele N; Hawkins JA; Ito Y; Wang J; Helmrath MA; Merchant JL; Ahmed SA; Shabbir A; Yan So JB; Yong WP; Zavros Y
Cancer Lett; 2021 Oct; 518():59-71. PubMed ID: 34126195
[TBL] [Abstract][Full Text] [Related]
2. Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection.
Holokai L; Chakrabarti J; Broda T; Chang J; Hawkins JA; Sundaram N; Wroblewski LE; Peek RM; Wang J; Helmrath M; Wells JM; Zavros Y
PLoS Pathog; 2019 Jan; 15(1):e1007468. PubMed ID: 30703170
[TBL] [Abstract][Full Text] [Related]
3. Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids.
Chakrabarti J; Koh V; Steele N; Hawkins J; Ito Y; Merchant JL; Wang J; Helmrath MA; Ahmad SA; So JBY; Yong WP; Zavros Y
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944780
[TBL] [Abstract][Full Text] [Related]
4. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma.
Holokai L; Chakrabarti J; Lundy J; Croagh D; Adhikary P; Richards SS; Woodson C; Steele N; Kuester R; Scott A; Khreiss M; Frankel T; Merchant J; Jenkins BJ; Wang J; Shroff RT; Ahmad SA; Zavros Y
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33348809
[No Abstract] [Full Text] [Related]
5. A Preclinical Human-Derived Autologous Gastric Cancer Organoid/Immune Cell Co-Culture Model to Predict the Efficacy of Targeted Therapies.
Chakrabarti J; Koh V; So JBY; Yong WP; Zavros Y
J Vis Exp; 2021 Jul; (173):. PubMed ID: 34309588
[TBL] [Abstract][Full Text] [Related]
6. Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer.
Chakrabarti J; Holokai L; Syu L; Steele NG; Chang J; Wang J; Ahmed S; Dlugosz A; Zavros Y
Oncotarget; 2018 Dec; 9(100):37439-37457. PubMed ID: 30647844
[TBL] [Abstract][Full Text] [Related]
7. Mouse-Derived Gastric Organoid and Immune Cell Co-culture for the Study of the Tumor Microenvironment.
Chakrabarti J; Holokai L; Syu L; Steele N; Chang J; Dlugosz A; Zavros Y
Methods Mol Biol; 2018; 1817():157-168. PubMed ID: 29959712
[TBL] [Abstract][Full Text] [Related]
8. JAK-STAT1 Signaling Pathway Is an Early Response to
Li X; Pan K; Vieth M; Gerhard M; Li W; Mejías-Luque R
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456965
[No Abstract] [Full Text] [Related]
9. PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice.
Kim W; Chu TH; Nienhüser H; Jiang Z; Del Portillo A; Remotti HE; White RA; Hayakawa Y; Tomita H; Fox JG; Drake CG; Wang TC
Gastroenterology; 2021 Feb; 160(3):781-796. PubMed ID: 33129844
[TBL] [Abstract][Full Text] [Related]
10. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer.
Mimura K; Teh JL; Okayama H; Shiraishi K; Kua LF; Koh V; Smoot DT; Ashktorab H; Oike T; Suzuki Y; Fazreen Z; Asuncion BR; Shabbir A; Yong WP; So J; Soong R; Kono K
Cancer Sci; 2018 Jan; 109(1):43-53. PubMed ID: 29034543
[TBL] [Abstract][Full Text] [Related]
13. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
14. AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer.
Spirina LV; Avgustinovich AV; Afanas'ev SG; Kondakova IV; Volkov MY; Dobrodeev AY; Boronkina AI
Bull Exp Biol Med; 2020 Nov; 170(1):75-78. PubMed ID: 33231797
[TBL] [Abstract][Full Text] [Related]
15. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
[TBL] [Abstract][Full Text] [Related]
16. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
17. New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.
Gullo I; Oliveira P; Athelogou M; Gonçalves G; Pinto ML; Carvalho J; Valente A; Pinheiro H; Andrade S; Almeida GM; Huss R; Das K; Tan P; Machado JC; Oliveira C; Carneiro F
Gastric Cancer; 2019 Jan; 22(1):77-90. PubMed ID: 29779068
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
Liang Y; Wang W; Zhu X; Yu M; Zhou C
Sci Rep; 2022 Jun; 12(1):9619. PubMed ID: 35688951
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
Duraiswamy J; Freeman GJ; Coukos G
Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
